Update on Chemotherapy in the Treatment of Urothelial Carcinoma

Table 2

Ongoing clinical trials with targeted agents in urothelial carcinoma.

Phase	Cohort	Subjects	Treatment	Protocol number
I/II	Noncystectomy candidates undergoing radiation in muscle-invasive disease	88	Paclitaxel ± trastuzumab	NCT00238420
I	First line metastatic/advanced	25	GC with lapatinib	NCT00623064
II/III	Maintenance after first-line metastatic/advanced	204	Lapatinib versus placebo	NCT00949455
II	First-line metastatic/advanced	86	GC ± cetuximab	NCT00645593
II	First-line metastatic/advanced	51	GC with bevacizumab	NCT00588666
III	First-line metastatic/advanced	500	GC ± bevacizumab	NCT00942331
II	Neoadjuvant/adjuvant	25	Neoadjuvant GC with bevacizumab; Adjuvant paclitaxel with bevacizumab	NCT00268450
II	Neoadjuvant	45	GC with sunitinib	NCT00847015
II	Adjuvant	33	Sunitinib (after neoadjuvant platinum-based chemotherapy)	NCT01042795
II	First-line cisplatin ineligible metastatic/advanced	41	Sunitinib	NCT01118039
II	First-line metastatic/advanced	63	GC with sunitinib	NCT01089088
II	Neoadjuvant	45	GC with sorafenib	NCT01222676
II	First line metastatic/advanced	30	GC with sorafenib	NCT00461851
I	Non-cystectomy candidates undergoing radiation in muscle invasive disease	18	Sorafenib	NCT00544609
II	Second-line cisplatin pretreated metastatic/advanced	41	Pazopanib	NCT01031875
II	Second- or third-line metastatic	32	Pazopanib with weekly paclitaxel	NCT01108055
Pilot	Neoadjuvant	25	Dasatinib	NCT00706641
II	First-line cisplatin ineligible metastatic/advanced	122	Carboplatin/Gemcitabine ± vandetanib	NCT01191892

*Data from http://www.clinicaltrials.gov/ accessed on April 2011.